| http://www.w3.org/ns/prov#value | - Usually, although not in all cases, it will be desirable that the epitopic site be immunologically distinct from (i.e., not cross-reactive withimmunoglobulins which recognize) viruses other than FIV. It is desirable to have an epitopic site that is common to viruses related to FIV, such as human immunodeficiency virus (HIV), when the present invention is used to treat, detect, or vaccinateagainst
|
